aml-hub.com

• charset: utf-8
• name: viewport content: width=device-width, initial-scale=1
• name: description content: in partnership with the European LeukemiaNet (ELN).
• property: og:title content: Home | AML Hub
• property: og:description content: in partnership with the European LeukemiaNet (ELN).
• property: og:url content: https://aml-hub.com
• property: og:site_name content: AML Hub
• property: og:locale content: en_US
• property: og:image content: https://aml-hub.com/images/share/og-aml.png
• property: og:image:width content: 1200
• property: og:image:height content: 1200
• property: og:type content: website
• name: twitter:card content: summary_large_image
• name: twitter:title content: Home | AML Hub
• name: twitter:description content: in partnership with the European LeukemiaNet (ELN).
• name: twitter:image content: https://aml-hub.com/images/share/og-aml.png
• name: twitter:image:width content: 1200
• name: twitter:image:height content: 1200

• http://aml-hub.com/#
• http://aml-hub.com/steering-committees
• http://aml-hub.com/about-us
• Newsletter
• http://aml-hub.com/contact
• http://aml-hub.com/our-hubs
• http://aml-hub.com/account
• MY BOOKMARKED CONTENT
• ACCOUNT SETTINGS
• http://aml-hub.com/
• View funders
• http://aml-hub.com/types
• http://aml-hub.com/therapeutics
• http://aml-hub.com/congresses
• http://aml-hub.com/trials
• http://aml-hub.com/expert-opinions
• VIEW ALL
• http://aml-hub.com/educational-resources
• VIEW ALL
• Privacy Policy
• http://aml-hub.com/medical-information/clad-ldac-ven-or-aza-ven-for-older-or-unfit-patients-with-nd-aml-phase-ii-results
• http://aml-hub.com/types/disease-type/newly-diagnosed
• http://aml-hub.com/medical-information/identifying-fusionstranslocations-with-ngs-an-analysis-of-myelomatch
• http://aml-hub.com/congresses/ash/ash-2024
• http://aml-hub.com/medical-information/congresses-asco26
• http://aml-hub.com/congresses/asco/asco-2026
• http://aml-hub.com/medical-information/beat-aml-prognostic-impact-of-idh-mutations-in-older-patients-with-nd-aml
• http://aml-hub.com/types/aml-related-mutations/idh2
• https://aml-hub.com/medical-information/ash-2025-top-abstracts-whats-hot-in-acute-myeloid-leukemia
• https://aml-hub.com/medical-information/symposium-series-understanding-the-differences-between-flt3-itd-and-tkd-mutations-in-aml-implications-for-clinical-practice
• http://aml-hub.com/medical-information/quiwi-phase-ii-post-hoc-analysis-quizartinib-and-allo-hsct-in-nd-flt3-itd-negative-aml
• http://aml-hub.com/medical-information/eln-2022-eln-2024-and-beat-aml-2024-treatment-specific-prognostic-validation-for-aml
• http://aml-hub.com/types/risk
• http://aml-hub.com/medical-information/fda-grants-orphan-drug-designation-to-cln-049-for-the-treatment-of-rr-aml
• http://aml-hub.com/types/disease-type/relapsedrefractory
• http://aml-hub.com/medical-information/ic-vs-hma-ven-for-nd-aml-with-very-high-risk-cytogenetic-features
• http://aml-hub.com/types/risk/high-risk
• http://aml-hub.com/medical-information/menin-inhibitors-in-aml-where-are-we-now-and-where-are-we-going
• http://aml-hub.com/therapeutics/menin-inhibitors
• http://aml-hub.com/medical-information/2022-eln-recommendations-for-the-diagnosis-of-aml-in-adults
• http://aml-hub.com/medical-information/treatment-decisions-in-aml-personalizing-care-with-flt3-inhibitor-therapy
• http://aml-hub.com/types/aml-related-mutations/flt3-tkd-1
• http://aml-hub.com/medical-information/ash-2025-paradigm-azacitidine-venetoclax-vs-conventional-induction-chemotherapy-in-fit-adults-with-nd-aml
• http://aml-hub.com/congresses/ash/ash-2025
• VIEW ALL
• http://aml-hub.com/medical-information/know-aml-webinar-closing-remarks-and-qa
• http://aml-hub.com/medical-information/know-aml-webinar-how-can-physicians-and-patients-communicate-more-clearly-about-mutation-testing-in-aml-going-forward
• http://aml-hub.com/medical-information/know-aml-webinar-empowering-patients-to-ask-their-physician-the-right-questions-during-their-aml-journey
• http://aml-hub.com/medical-information/know-aml-webinar-what-are-mutations-and-why-do-they-matter-in-aml
• VIEW ALL
• http://aml-hub.com/medical-information/addressing-uncertainty-in-patient-selection-for-transplant-in-aml
• http://aml-hub.com/therapeutics/cellular-therapy/allo-hsct
• http://aml-hub.com/medical-information/how-can-we-intervene-with-mrd-directed-therapy-within-and-outside-of-transplantation
• http://aml-hub.com/drug-updates/2057110380132905275
• http://aml-hub.com/drug-updates/2055204551779611020
• http://aml-hub.com/drug-updates/2024126025752285563
• http://aml-hub.com/drug-updates/2011454713229647890
• contact us.
• Terms and Conditions
• Cookie Policy

• Know AML
• Google Translate Help
• https://x.com/AML_Hub
• https://www.instagram.com/aml_hub/
• https://www.facebook.com/AMLHub/
• https://www.linkedin.com/company/aml-hub
• https://www.youtube.com/@amlhub4206
• Brought to you by
• https://donate.stripe.com/6oEeYjbye92QbN68ww
• https://buy.stripe.com/fZebM76dU7YMbN63cd
• Find out more
• https://scientificeducationsupport.com/news-and-events/celebrating-10-years-of-the-aml-hub/
• https://know-aml.com/get-involved/world-awareness-day
• @US_FDA
• https://bit.ly/4v5yIdD
• https://bit.ly/4wBMgzc
• https://prn.to/4kHs0Gs
• https://loom.ly/pafco0A
• https://www.scientificeducationsupport.com
• https://www.leukemia-net.org/
• https://www.jnj.com/
• https://www.daiichisankyo.com/
• https://kuraoncology.com/
• https://www.thermofisher.com/
• https://syndax.com/
• https://www.abbvie.com/

            Domain Name: AML-HUB.COM
Registrar: GoDaddy.com, LLC
Domain Status: client delete prohibited
Domain Status: client renew prohibited
Domain Status: client transfer prohibited
Domain Status: client update prohibited
Creation Date: 2014-07-31T15:50:17Z
Registry Expiry Date: 2026-07-31T15:50:17Z
Updated Date: 2025-08-01T10:22:54Z
Name Server: NS1.DIGITALOCEAN.COM
Name Server: NS2.DIGITALOCEAN.COM
Name Server: NS3.DIGITALOCEAN.COM
REGISTRAR Contact: GoDaddy.com, LLC
>>> Last update of RDAP database: 2026-07-30T17:53:27Z         

			User-agent: *
Allow: /        

Techniczne SEO

SEO na stronie

Treść i UX